Last reviewed · How we verify

MS Contin

National Institute of Nursing Research (NINR) · FDA-approved active Small molecule

MS Contin is a sustained-release formulation of morphine sulfate that binds to opioid receptors in the central nervous system to reduce pain perception.

MS Contin is a sustained-release formulation of morphine sulfate that binds to opioid receptors in the central nervous system to reduce pain perception. Used for Moderate to severe chronic pain in opioid-tolerant patients, Cancer pain.

At a glance

Generic nameMS Contin
Also known asoxycodone, morphine
SponsorNational Institute of Nursing Research (NINR)
Drug classOpioid analgesic
TargetMu-opioid receptor (μ-OR)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Morphine is a mu-opioid receptor agonist that decreases pain signaling by binding to opioid receptors in the brain and spinal cord. The sustained-release formulation provides continuous drug delivery over 8-12 hours, allowing for less frequent dosing compared to immediate-release formulations. This mechanism makes it suitable for chronic pain management in opioid-tolerant patients.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: